Therapeutic drug monitoring value for isavuconazole in special population

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600116582

Enrollment

Unknown

Registered

2026-01-12

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive mold disease

Interventions

Isavuconazole TDM Cohort in Special Populations:NA

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients (age >=18 years); 2. Scheduled to receive isavuconazole therapy; 3. With a Child-Pugh class B or C score; or receiving renal replacement therapy; or undergoing extracorporeal membrane oxygenation; 4. Agreement to undergo therapeutic drug monitoring (TDM) for isavuconazole.

Exclusion criteria

Exclusion criteria: 1. Known allergy or hypersensitivity to isavuconazole; 2. Positive pregnancy test or ongoing lactation; 3. Concurrent participation in another clinical trial.

Design outcomes

Primary

Measure	Time frame
Plasma concentration of isavuconazole during the loading dose phase;Plasma concentration of isavuconazole during CRRT and/or ECMO;Plasma concentration of isavuconazole during the maintenance dose phase;	—

Countries

China

Contacts

Public ContactZhang Chunhong

The First Affiliated Hospital of Wenzhou Medical University

zch760217@163.com+86 577 55579708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026